Last checked at 21 Apr 2021 07:00
21 April 2021
Diaceutics PLC
("Diaceutics" or the "Company")
Notice of AGM and Posting of Annual Report
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it will today post its Annual Report for the year ended 31 December 2020 to shareholders together with the Notice of the 2021 Annual General Meeting ("AGM").
The Board of Directors (the "Board") takes its responsibility to safeguard the health of its shareholders, stakeholders and employees seriously. In accordance with the UK Government's instructions at the time of writing, and to minimise public health risks, we strongly recommend that shareholders do not physically attend the AGM, which will be held at 2pm on Wednesday 19 May 2021 at 55-59 Adelaide Street, Belfast BT2 8FE. The AGM will be convened with the minimum necessary quorum of two shareholders (which will be facilitated by the Company).
The Board requests that shareholders vote on the resolutions being put to the AGM by appointing the Chairman of the AGM as a proxy and giving voting instructions in advance, either through the CREST system, by using the Form of Proxy accompanying the Notice of 2021 AGM or by appointing a proxy at www.signalshares.com.
The Board understands that the AGM also serves as a forum for shareholders to raise questions and comments. Therefore, if shareholders do have any questions or comments relating to the business of the meeting then they are asked to submit those questions in writing via email to investorrelations@diaceutics.com by no later than 2pm on Monday 17 May 2021. The Board will endeavour to publish answers to any frequently asked questions on the Company's website as soon as practicable after the AGM.
The Annual Report and Notice of AGM will also be available shortly on the Company's website at www.diaceutics.com.
Enquiries:
Diaceutics PLC | www.diaceutics.com | ||
Peter Keeling, Chief Executive Officer | via Walbrook PR | ||
Philip White, Chief Financial Officer | |||
Cenkos Securities plc (Nominated adviser and broker) | +44 (0)207 397 8900 | ||
Callum Davidson / Giles Balleny | |||
Michael Johnson (Sales) | |||
Walbrook PR | Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com | ||
Anna Dunphy | Mob: +44 (0)7876 741 001 | ||
Paul McManus | Mob: +44 (0)7980 541 893 | ||
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world's leading pharmaceutical companies. DXRX - The Diagnostic Network® provides unrivalled access to deep analysis and insights from the world's largest repository of diagnostic testing data on one secure platform.
About DXRX - The Diagnostic Network®
DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.